Consumption of lycopene, an antioxidant naturally present in tomato products, has been inversely associated with the risk of developing prostate cancer. We set out to measure serum and prostate tissue lycopene as well as other markers of oxidative stress (OS) among prostate cancer patients and controls.
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Method Subject
Cases (n 24) were surgical candidates with untreated prostate cancer (PCa). Controls (n 18) were men presenting for transurethral resection (TURP) (n 12) or radical cystoprostatectomy (n 6). All men provided informed consent and completed a baseline evaluation form including a standardised fruit and vegetable intake questionnaire.
Serum and prostate tissue collection
Fasting blood was obtained prior to surgical incisions. For men who underwent open prostatectomy, biopsy specimens were obtained immediately after specimen removal. For TURP patients, cold cup biopsies were taken prior to electroresection. Pathologic review selected specimens free of malignant tissue.
Oxidative biomarker analysis
Lycopene levels were measured via HPLC. Lipid oxidation was estimated via malondialdehyde (MDA) determination and protein oxidation via the 5,5 0 -dithio-bis (2-nitrobenzoic acid) (DTNB) assay.
Results
No signi®cant differences were noted between the 2 groups in terms of: age; height; weight; smoking status; vegetable and fruit intake; or tomato product consumption.
Lycopene
Lycopene was 41% lower in the serum (P`0.05) and 36% lower (P`0.05) within the benign prostate tissue among cases compared to controls.
Protein and lipid oxidation markers
Reduced thiol groups were lower (indicating increased OS) (P`0.05) and MDA levels were insigni®cantly (17%, P b 0.05) higher among cases than controls.
Conclusion
These data con®rm that oxidative marker levels are associated with prostate cancer.
